维普中文期刊产品整合服务
139篇 您的检索式:作者名="Hussein O"
    题名 作者 年代 出处 被引量
1Cycling of antibiotics for the prophylaxis of recurrent spontaneous bacterial peritonitis in a cirrhotic patient显示文摘TO THE EDITOR More than 80% of cirrhotic patients who have been treated successfully for spontaneous bacterial peritonitis (SBP)experience a recurrence[1,2]. Long-term prophylaxis with single daily oral antibiotic has been shown to be cost effective in delaying a recurrence but only for a short time[3].What has never been tested in this population is the cycling of antibiotics. We report the beneficial use of antibiotic cycling for 36 weeks in a 74-year-old woman with cryptogenic cirrhosis and recurrent SBP.N Assy S Schlesinger D Miron O Hussein 2005World Journal of Gastroenterology2005,11,41:3
2Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases显示文摘AIM: To evaluate the prevalence of genetic and acquired prothrombotic risk factors and their association with the extent of fibrosis and fatty infiltration in patients with non-alcoholic fatty liver disease (NAFLD).METHODS: Forty-four patients with chronic hepatitis (28 men and 16 women, with mean age of 45±11 and 49±12 years, respectively) constituted the patient population of this study. The groups were divided as follows: 15 patients with fatty liver (FL); 15 with non-alcoholic steatohepatitis (NASH); 14 with chronic viral hepatitis (CH) diagnosed by histology and liver technetium scan or ultrasound; and 10 healthy individuals. Thrombophilic, coagulation factors and genetic mutations were diagnosed by standard hemostatic and molecular coagulation assays.RESULTS: Activated protein C (APC) resistance and protein S were the most prevalent thrombotic risk factors (6% and 10% in NAFLD vs 21% and 14% in CH; P<0.01 and P<0.05, respectively). One thrombotic risk factor was identified in 41% of patients (23% mild fibrosis, 18% severe fibrosis) and two thrombotic risk factors in 6% of patients with NAFLD and severe fibrosis. While no differences in APC ratio, lupus anticoagulant, fibrinogen, factor V Leiden,prothrombin, and MTHFR mutation were found. Protein S levels were significantly lower in NASH patients than in patients with FL alone (92±19 vs106±2, P<0.01). Protein C levels were markedly higher in patients with NAFLD and mild or severe fibrosis as compared to the patients with CH, respectively (128±40 vs96±14, P<0.001 or 129±36 vs 88±13, P<0.01).CONCLUSION: Up to 46% of patients with NAFLD may have thrombotic risk factors, and the presence of thrombotic risk factors is correlated with the extent of hepatic fibrosis,suggesting a crucial role of the coagulation system in the pathogenesis of hepatic fibrosis.N Assy I Bekirov Y Mejritsky L Solomon S Szvalb O Hussein 2005World Journal of Gastroenterology2005,11,37:3
3Retrospective population pharma cokinetic analysis of cetirizine in children aged 6 months to 12 years显示文摘Pitsiu M Hussein Z Majid O 2004Br J Glin Pharmacol2004,57,4:1
4Steep Dispersion and Group Velocity Below c/3000 in Coherent Population Trapping显示文摘SCHMIDT O WYNANDS R HUSSEIN Z 0,,:1
5Nematode acetylcholinesterases are encoded by multiple genes and perform non-overlapping functions显示文摘SELKIRK M E LAZARI O HUSSEIN A S 2005Chem Biol Interact2005,,:1
6Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma 显示文摘ZIDAN J HUSSEIN O BASHER W 2004Oncologist2004,9,4:1
7Self-assembled Nanocomposite of Organic-inorganic Hybrid显示文摘Hussein M Z B Zainal Z Tat O W S 2000Journal of Chemistry2000,16,2:1
8The effect of current mode and discharge type on the corrosion resistance of plasma electrolytic oxidation (PEO) coated magnesium alloy AJ62显示文摘Hussein R O Zhang P Nie X 2011Surface and Coatings Technology2011,206,:1
9Video-assisted axillary surgery for cancer: non-randomized comparison with conventional techniques 显示文摘Hussein O EI-Nahhas W EI-Saed A el al 2007Breast2007,16,5:1
10Serum CA125: a tumor marker for monitoring response to treatment and followup in patients with non-Hodgkin ' s lymphoma 显示文摘Zidan J Hussein O Basher W 2004Oneologist2004,9,4:1
11Spectroscopic study of electrolytic plasma and discharging behaviour during the plasma electrolytic oxidation (PEO) process显示文摘R O Hussein X Nie D O Northwood A Yerokhin A Matthews 2010Journal of Physics D: Applied Physics2010,,10:1
12Serum CA125 :a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma显示文摘Zidan J Hussein O Basher W 2004Oncologist2004,9,:1
13Laser subepithelial keratomileusis for the correction of high myopia with the schwind esiris scanning spot laser 显示文摘O' Brart DPS Attar MA Hussein B 2006J Refract Surg2006,22,:1
14Deaths in children during an outbreak of hand, foot, and mouth disease in Peninsular Malaysia--clin- ical and pathological characteristics 显示文摘Shekhar K Lye MS Norlijah O Ong F Looi LM Khuzai- ah R Marzuki I Hussein I Wong SL Mohan J Sinniah M Abu Bakar S 2005Med J Malaysia2005,60,3:1
15Severe hepatotoxicity associated with the combination of spiramycin plus metronidazole显示文摘Hussein R El-Halabi M Ghaith O 2011Arab J Gastroenterol2011,12,1:1
16Phytoremediation of Mercury and Organomercurials in Chloroplast Transgenic Plants: Enhanced Root Uptake, Translocation to Shoots, and Volatilization 显示文摘HUSSEIN H S RUIZ O N TERRY N 2007Environmental Science and Technology2007,41,24:1
17Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation:studies in hypercholesterolemic and hypertensive patients显示文摘Hussein O Shneider J Rosenblat M 2002J Cardiovasc Pharmacol2002,40,:1
18Interactions of Platelets,Macrophages,and Lipoproteins in Hypercholesterolemia:Antiatherogenic Effects of HMGCoA Reductase Inhibitor Therapy显示文摘Aviram M Hussein O Rosenblat M 1998J Cardiovasc Pharmacol1998,31,1:1
19An evaluation of the Sysmex NE-8000 hematology analyzer显示文摘Hallawell R O Malley C Hussein S 1991Am J Clin Pathol1991,96,:1
20Arterial elasticity in obese subjects with coronary slow flow phenomenon显示文摘Hussein O Zidan J Plich M 2013Isr Med Assoc J2013,15,12:1
返回顶部 每页显示:
共7页 首页 上一页 第1页 下一页 末页 /7 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费